Background:Our team devised a real-time telemonitoring system (THYRPAN-TM) for measurement of the radiation exposure rate during the hospitalization of patients treated with high doses of radioiodine in the special premises with restricted access (“restricted area” [RA]).Subjects and Methods:The THYRPAN-TM prototype was tested for stability, efficacy, and linearity in a 32-day measurement of a 110 MBq 131I source. Furthermore, it was tested on 15 patients with differentiated thyroid carcinoma who stayed in the RA for 3 days, following their radioiodine treatment.Results:Minor deviation from the theoretical values was detected when the 131I source was measured by the THYRPAN-TM, but only at the beginning of the measurement (7.20%).Conclusions:THYRPAN-TM is a stable, user-friendly detection system for the measurement of the exposure rate following radioiodine administration. It enables the telemonitoring of patients, as well as real-time and online measurement of the whole-body burden of 131I.
Get full access to this article
View all access options for this article.
References
1.
SeidlinS, OshryE, YallowAA. Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma. J Clin Endocrinol Metab, 1948; 8:423–425.
2.
CooperDS, DohertyGM, HaugenBR, et al.The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2006; 16:1–34.
3.
PaciniF, SchlumbergerM, DralleH, et al.The European Thyroid Cancer Taskforce. Consensus statement. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 2006; 154:787–803.
4.
VenenciaCD, GermanierAG, BustosSR, GiovanniniAA, WyseEP. Hospital discharge of patients with thyroid carcinoma treated with 131I. J Nucl Med, 2002; 43:61–65.
5.
Tuttle WKIII, BrownPH. Applying Nuclear Regulatory Commission guidelines to the release of patients treated with sodium iodine-131. J Nucl Med Technol, 2000; 28:275–279.
6.
MatovicM, JankovicS, JeremicM, VlajkovicM, MatovicV. On-line remote monitoring of patients with differentiated thyroid carcinomas (DTC) and neuroendocrine tumors (NET) treated with high doses of radionuclides. Telemed J E Health, 2012; 18:264–270.
7.
ZuckierLS, BoardmanB, ZhaoQH. Remotely pollable Geiger-Muller detector for continuous monitoring of iodine-131 therapy patients. J Nucl Med, 1998; 39:1558–1562.
8.
MatovicM. Preparation for radioiodine therapy: How to increase therapeutic efficacy and accelerate unbound radioiodine excretion. Vojnosanit Pregl, 2013; 70:504–510.
